KR102748255B1 - 종양성 질병들에 대한 치료 - Google Patents

종양성 질병들에 대한 치료 Download PDF

Info

Publication number
KR102748255B1
KR102748255B1 KR1020247029350A KR20247029350A KR102748255B1 KR 102748255 B1 KR102748255 B1 KR 102748255B1 KR 1020247029350 A KR1020247029350 A KR 1020247029350A KR 20247029350 A KR20247029350 A KR 20247029350A KR 102748255 B1 KR102748255 B1 KR 102748255B1
Authority
KR
South Korea
Prior art keywords
subject
pharmaceutical composition
neoplastic disease
human
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247029350A
Other languages
English (en)
Korean (ko)
Other versions
KR20240134401A (ko
Inventor
존 시마드
Original Assignee
엑스바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스바이오테크 인코포레이티드 filed Critical 엑스바이오테크 인코포레이티드
Publication of KR20240134401A publication Critical patent/KR20240134401A/ko
Application granted granted Critical
Publication of KR102748255B1 publication Critical patent/KR102748255B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020247029350A 2010-08-23 2011-08-23 종양성 질병들에 대한 치료 Active KR102748255B1 (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US37609710P 2010-08-23 2010-08-23
US61/376,097 2010-08-23
US40675910P 2010-10-26 2010-10-26
US61/406,759 2010-10-26
US41118310P 2010-11-08 2010-11-08
US61/411,183 2010-11-08
US201161480635P 2011-04-29 2011-04-29
US61/480,635 2011-04-29
KR1020217032773A KR20210128021A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
PCT/US2011/048747 WO2012027324A2 (en) 2010-08-23 2011-08-23 Treatment for neoplastic diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217032773A Division KR20210128021A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료

Publications (2)

Publication Number Publication Date
KR20240134401A KR20240134401A (ko) 2024-09-09
KR102748255B1 true KR102748255B1 (ko) 2024-12-31

Family

ID=45594256

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020247029350A Active KR102748255B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020167013067A Ceased KR20160062200A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020217032773A Ceased KR20210128021A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020187029749A Active KR102104296B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020207002089A Active KR102314003B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020177026757A Active KR101910760B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020137007024A Ceased KR20130108305A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료

Family Applications After (6)

Application Number Title Priority Date Filing Date
KR1020167013067A Ceased KR20160062200A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020217032773A Ceased KR20210128021A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020187029749A Active KR102104296B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020207002089A Active KR102314003B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020177026757A Active KR101910760B1 (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료
KR1020137007024A Ceased KR20130108305A (ko) 2010-08-23 2011-08-23 종양성 질병들에 대한 치료

Country Status (17)

Country Link
US (3) US10294296B2 (enExample)
EP (3) EP3075394B1 (enExample)
JP (5) JP6241932B2 (enExample)
KR (7) KR102748255B1 (enExample)
CN (3) CN107281488B (enExample)
AU (1) AU2011293554B9 (enExample)
DK (1) DK2608808T3 (enExample)
ES (2) ES2622482T3 (enExample)
IL (2) IL262856B (enExample)
MX (2) MX342776B (enExample)
NZ (1) NZ607472A (enExample)
PH (2) PH12013500316A1 (enExample)
PT (1) PT2608808T (enExample)
RU (2) RU2679119C2 (enExample)
SG (1) SG187853A1 (enExample)
WO (1) WO2012027324A2 (enExample)
ZA (1) ZA201301420B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
KR102748255B1 (ko) 2010-08-23 2024-12-31 엑스바이오테크 인코포레이티드 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP6204915B2 (ja) 2011-09-23 2017-09-27 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 悪液質治療
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US20170260285A1 (en) * 2014-11-24 2017-09-14 University Of Iowa Research Foundation Methods for treating cancer
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298096A1 (en) * 2008-05-30 2009-12-03 Xbiotech, Inc. Interleukin-1 alpha ABS and methods of use
US20100040574A1 (en) * 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2049342A1 (en) 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
US5407431A (en) 1989-07-11 1995-04-18 Med-Design Inc. Intravenous catheter insertion device with retractable needle
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0664713B1 (en) 1992-10-14 2000-01-19 Nycomed Imaging As Therapeutic and diagnostic imaging compositions and methods
DK0614984T4 (da) 1993-03-05 2010-12-20 Bayer Healthcare Llc Humane monoklonale anti-TNF-alfa-antistoffer
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
AU778611B2 (en) * 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
DE19943790C2 (de) 1999-09-13 2001-11-15 Ericsson Telefon Ab L M Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten
US6380129B1 (en) 1999-11-02 2002-04-30 Richard J. Kraemer Enhanced materials for treatment of contamination
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
CA2426384A1 (en) 2000-10-19 2003-04-17 Kyowa Hakko Kogyo Co., Ltd. Antibody inhibiting vplf activity
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7348003B2 (en) * 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
CN100522999C (zh) 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
ES2871905T3 (es) 2002-03-01 2021-11-02 Immunomedics Inc Inmunoconjugado que comprende anticuerpos de RS7 humanizados
PL377091A1 (pl) 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
JP4667383B2 (ja) 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
KR100493102B1 (ko) 2003-06-30 2005-06-02 삼성전자주식회사 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
WO2006062779A2 (en) * 2004-12-09 2006-06-15 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
CN109187944A (zh) 2005-08-02 2019-01-11 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20080047564A (ko) 2005-09-28 2008-05-29 사이토스 바이오테크놀로지 아게 인터루킨-1 컨쥬게이트 및 그의 용도
CA2648223A1 (en) 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
AU2007251239B2 (en) 2006-05-15 2013-08-22 Xbiotech Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
JP2011521896A (ja) 2008-04-15 2011-07-28 サーコード コーポレイション 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト
WO2010030979A2 (en) 2008-09-12 2010-03-18 Xbiotech, Inc. Targeting pathogenic monocytes
ES2466341T3 (es) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
PE20120586A1 (es) 2009-01-29 2012-06-17 Abbott Lab Proteinas de union a il-1
FR2945396A1 (fr) * 2009-05-07 2010-11-12 St Microelectronics Grenoble 2 Procede et dispositif d'analyse de la propagation de transactions dans un reseau multi-protocoles d'un systeme sur puce
TW201124427A (en) 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
CN105056232A (zh) 2010-06-03 2015-11-18 阿布维生物技术有限公司 用于治疗化脓性汗腺炎(hs)的用途和组合物
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
KR102748255B1 (ko) 2010-08-23 2024-12-31 엑스바이오테크 인코포레이티드 종양성 질병들에 대한 치료
NZ607510A (en) 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
EP2694107B1 (en) 2011-04-01 2018-08-22 XBiotech, Inc Treatment for dermatological pathologies
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。
JP6204915B2 (ja) 2011-09-23 2017-09-27 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 悪液質治療
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP4628162A3 (en) 2012-10-04 2025-12-03 XBiotech Inc. Treating vascular disease and complications thereof
CA2886757C (en) 2012-10-04 2022-04-05 Xbiotech Inc. Treatment of anxiety with il1.alpha. antagonist
US9809645B2 (en) 2013-03-12 2017-11-07 Zenyaku Kogyo Kabushikikaisha Anti-Staphylococcus antibody, method for manufacturing same, and usage of same
US20150024031A1 (en) 2013-07-17 2015-01-22 Baxter International Inc. Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
WO2015187779A1 (en) 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100040574A1 (en) * 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
US20090298096A1 (en) * 2008-05-30 2009-12-03 Xbiotech, Inc. Interleukin-1 alpha ABS and methods of use

Also Published As

Publication number Publication date
IL275350A (en) 2020-07-30
EP2608808A4 (en) 2014-01-15
MX2013002160A (es) 2013-04-05
MX342776B (es) 2016-10-12
US20230382989A1 (en) 2023-11-30
JP6241932B2 (ja) 2017-12-06
KR20240134401A (ko) 2024-09-09
PH12016500578B1 (en) 2017-03-06
ES2622482T3 (es) 2017-07-06
EP2608808B1 (en) 2017-01-18
KR20130108305A (ko) 2013-10-02
US11932688B2 (en) 2024-03-19
KR102104296B1 (ko) 2020-04-27
PH12016500578A1 (en) 2017-03-06
EP3075394B1 (en) 2018-11-28
JP2016175939A (ja) 2016-10-06
EP2608808A2 (en) 2013-07-03
CN107281488A (zh) 2017-10-24
KR20200010609A (ko) 2020-01-30
AU2011293554B9 (en) 2015-03-19
KR20170113687A (ko) 2017-10-12
EP3443985A1 (en) 2019-02-20
AU2011293554B2 (en) 2015-02-26
SG187853A1 (en) 2013-03-28
US10294296B2 (en) 2019-05-21
JP2013536236A (ja) 2013-09-19
PT2608808T (pt) 2017-04-24
KR20180116458A (ko) 2018-10-24
RU2679119C2 (ru) 2019-02-06
JP2019194233A (ja) 2019-11-07
JP2025166117A (ja) 2025-11-05
KR20160062200A (ko) 2016-06-01
RU2013110030A (ru) 2014-09-27
IL262856A (en) 2018-12-31
MX388939B (es) 2025-03-20
JP2021138750A (ja) 2021-09-16
IL262856B (en) 2020-06-30
JP7316120B2 (ja) 2023-07-27
IL275350B (en) 2021-07-29
DK2608808T3 (en) 2017-04-24
RU2017112088A (ru) 2019-01-24
CN107252484A (zh) 2017-10-17
KR101910760B1 (ko) 2018-10-22
KR20210128021A (ko) 2021-10-25
WO2012027324A3 (en) 2012-05-10
EP3075394A1 (en) 2016-10-05
US20190127460A1 (en) 2019-05-02
EP3443985B1 (en) 2020-12-16
ZA201301420B (en) 2014-04-30
US20120045444A1 (en) 2012-02-23
NZ607472A (en) 2014-09-26
AU2011293554A1 (en) 2013-03-07
JP6917681B2 (ja) 2021-08-11
KR102314003B1 (ko) 2021-10-19
WO2012027324A2 (en) 2012-03-01
ES2856723T3 (es) 2021-09-28
PH12013500316A1 (en) 2016-09-02
CN107281488B (zh) 2021-02-09
CN103153340A (zh) 2013-06-12
RU2017112088A3 (enExample) 2019-01-24

Similar Documents

Publication Publication Date Title
JP7316120B2 (ja) 腫瘍性疾患のための治療
AU2015201228B2 (en) Treatment for neoplastic diseases
AU2015271978B2 (en) Treatment for neoplastic diseases
HK40002544B (en) Treatment for neoplastic diseases
HK40002544A (en) Treatment for neoplastic diseases
HK1229696B (en) Treatment for neoplastic diseases
HK1229696A1 (en) Treatment for neoplastic diseases
HK1182635A (en) Treatment for neoplastic diseases

Legal Events

Date Code Title Description
A111 Divisional application filed after appeal phase [split application]
PA0112 Separate application for international patent

St.27 status event code: A-0-1-A10-A16-div-PA0112

St.27 status event code: A-0-1-A10-A18-div-PA0112

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601